NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 17.20 against a street estimate of 14.77 — a beat of 16.5%.
with an average price target of ₹2,703.26.
CONFIDENT Mankind delivered strong Q2 growth, margin expansion and IPM outperformance, while chronic, BSV specialty and international businesses remained key growth drivers. Q2 FY27 International growth was broad-based; management expects emerging markets to increasingly outweigh the U.S. contribution. Analysts focused on export drivers, sustainable India outperformance, margins, consumer recovery, BSV momentum and Armed Cell funding. Management reiterated growth confidence, retained margin guidance and expects international double-digit growth. 2026-10-26…
Full summary in the app.
| Holder | Stake |
|---|---|
| NPS Trust- A/C LIC Pension Fund Scheme - State Gov | 2.65% |
| Nippon Life India Trustee Ltd-a/c Nippon India Ret | 2.45% |
| SBI Esg Exclusionary Strategy Fund | 1.49% |
| Aditya Birla Sun Life Mutual Fund - Aditya Birla S | 1.21% |
| Government Pension Fund Global | 1.06% |
| Document | Date |
|---|---|
| Q1 FY27 earnings call MANKIND PHARMA LIMITED – Q1 FY27 EARNINGS CALL SUMMARY HEADLINE NUMBERS • Total Revenue: INR 4,031 crores, up 13% year-on-year (INR 3,570 crores in | 2026-08-04 |
| Investor presentation MANKIND PHARMA LIMITED – Q1 FY27 INVESTOR SUMMARY --- HEADLINE NUMBERS • Revenue from Operations: INR 4,031 Cr in Q1 FY27, up 12.9% YoY from INR 3, | 2026-07-30 |
| Annual report FY2026 MANKIND PHARMA LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • 35th Annual General Meeting scheduled for Tuesday, August 4, 2026 at 3:30 P.M. (IST) vi | 2026-07-09 |
| Q4 FY26 earnings call MANKIND PHARMA LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Q4 FY26 revenue: INR 3,443 crores (11.8% YoY growth) vs INR 3,079 crores in Q4 FY25 • FY | 2026-05-26 |
| Quarterly results · Q4 FY26 MANKIND PHARMA LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Full Year FY2026 Revenue from Operations: ₹10,421.18 crores (vs ₹9,507.41 crores in FY2 | 2026-05-19 |
| Investor presentation MANKIND PHARMA LIMITED – Q4 & FY26 INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue: INR 14,278 Cr – 17.0% YoY growth (domestic INR 12,217 Cr up 14. | 2026-05-19 |
| Q3 FY26 earnings call MANKIND PHARMA LIMITED – Q3 & 9M FY26 EARNINGS CALL SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: INR 3,567 crores, up 11.5% YoY (Q3 FY25: INR 3,199 c | 2026-02-09 |
| Quarterly results · Q3 FY26 MANKIND PHARMA LIMITED – Q3 FY26 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: INR 3,567 Crore, up 11.5% YoY • Q3 FY26 Adjusted EBIT | 2026-02-03 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquisition of majority stake in Armed Cell Therapeutics for strategic CAR-T therapy entry Mankind Pharma will invest up to EUR 45 million more in its wholly owned Netherlands subsidiary, taking the approved investment limit to EUR 50 million including EUR 5 million previously app | 2026-10-15 |
| Acquisition announced Mankind Pharma will invest up to EUR 45 million more in its wholly owned Netherlands subsidiary, taking the approved investment limit to EUR 50 million (including EUR 5 million already appro | 2026-10-15 |
| Acquisition of another business or entity announced Mankind Pharma Limited has incorporated a wholly owned subsidiary company in the Netherlands named 'Mankind Pharma (Netherlands) B.V.' on August 13, 2026. This was a previously disclosed pla | 2026-08-13 |
| Final update on stake sale of Broadway Hospitality Services Final update on Stake Sale of Broadway Hospitality Services Private Limited | 2026-07-27 |
| Acquisition of another business announced Mankind Pharma Limited has informed the Exchange about Acquisition | 2026-07-11 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mankind Pharma Ltd — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.